http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2022246141-A2
Outgoing Links
Predicate | Object |
---|---|
assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ee602c630e57f59c6cfc1c1634e36064 |
classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-60 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-64 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K7-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K7-06 |
classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-48 |
filingDate | 2022-05-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4d216882f3702f4c51b36b2915984af8 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_77a3afe5a31be002154a95cbc756919e |
publicationDate | 2022-11-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber | WO-2022246141-A2 |
titleOfInvention | Peptide drug conjugates specific to fibronectin isotypes for cancer therapy |
abstract | An anticancer peptide conjugate is described that comprises the following formula: P-L-A wherein: P is a peptide that includes an amino acid sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, or variants thereof in which one or more L-amino acids have been replace with a corresponding D-amino acid; A is an antitumor agent; and L is an optional linker that covalently links the peptide to the antitumor agent, and pharmaceutically acceptable salts thereof. Methods of using the anticancer peptide conjugates to treat cancer are also described. |
priorityDate | 2021-05-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 245.